Revolutionizing Cancer Treatment: AI Innovations Presented at ASCO 2024
Key Takeaways
- Lunit's AI innovations are poised to transform precision oncology.
- Accurate HER2 quantification can expand treatment options for breast cancer patients.
- AI models enhance prediction of immunotherapy response in NSCLC.
Did You Know?
Introduction to ASCO 2024 Highlights
Lunit, a trailblazer in AI-powered cancer diagnostics and therapeutics, is set to present seven innovative studies at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting. From May 31 to June 4 in Chicago, Lunit will showcase advancements that stand to transform precision oncology.
Breakthrough in HER2 Quantification
One of the key highlights is Lunit's AI-powered HER2 analyzer, Lunit SCOPE HER2, which can identify HER2 ultra-low expression in breast cancer. This technology distinguishes true HER2-negative cases through continuous subcellular quantification from HER2 immunohistochemistry (IHC) images. The accurate identification of HER2 status broadens treatment options for patients previously classified as HER2-negative, potentially improving outcomes with HER2-targeted therapies.
Advancing Immunotherapy Prediction for NSCLC
Lunit's deep learning-based model integrates chest CT and histopathology analyses to predict the response to immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) patients. By evaluating pre-treatment chest CT scans, PD-L1 status, and immune phenotype, the model provides significant predictive power. This allows clinicians to tailor treatments more effectively, improving patient outcomes.
HER2-Targeted Therapies in Focus
Accurate identification of HER2 expression levels is crucial, given that HER2-targeted antibody-drug conjugates (ADCs) can effectively treat HER2-low breast cancers. Lunit's AI-based analyzer could reclassify cases initially considered HER2-negative. This reclassification opens new avenues for patients to receive targeted therapies, potentially increasing treatment efficacy.
Enhancing Predictive Accuracy with Combined Data
The predictive power of Lunit's models improves by combining chest CT images with histopathologic biomarkers such as PD-L1 expression and tumor-infiltrating lymphocytes (TILs). This combined approach enhances the accuracy of predicting ICI responses, showcasing the complementary strengths of imaging and pathology data.
Collaborative Studies and Their Impact
Collaboration with Stanford University School of Medicine has highlighted the heterogeneity of immune phenotypes in metastatic melanoma, providing insights into immunotherapy outcomes. Another study with Northwestern University demonstrated the predictive power of AI analysis of tertiary lymphoid structures (TLS) in NSCLC patients, further validating the role of AI in identifying key survival biomarkers.
Pioneering AI-Driven Precision Oncology
Brandon Suh, CEO of Lunit, emphasized the transformative potential of these studies in making cancer treatment personalized and predictive. By presenting these groundbreaking advancements, Lunit is setting new standards in AI-driven precision oncology.
Exploring Lunit SCOPE Suite Capabilities
Beyond the innovations already mentioned, Lunit will present additional studies highlighting the diverse applications of the Lunit SCOPE suite. These studies explore comprehensive histopathomic prediction models for early breast cancer and innovative approaches for treatment selection in TPS-high NSCLC.
Visit Lunit at ASCO 2024
Attendees of ASCO 2024 are invited to visit Lunit at booth IH22 to learn how the Lunit SCOPE suite is revolutionizing oncology research and clinical practice, reinforcing Lunit's commitment to advancing medical AI innovation.
About Lunit
Founded in 2013, Lunit is dedicated to conquering cancer through AI-powered medical image analytics and biomarkers. With its FDA-cleared Lunit INSIGHT suite utilized in over 3,000 hospitals globally, Lunit is at the forefront of ensuring accurate cancer diagnosis and optimal treatment.
In 2024, the acquisition of Volpara Health Technologies further strengthens Lunit's capabilities, particularly in breast health and screening technologies. Headquartered in Seoul, South Korea, Lunit continues its leadership in medical AI innovation, promising better patient outcomes worldwide.
